PL3067417T3 - Udoskonalone sposoby oczyszczania rekombinowanych wektorów AAV - Google Patents

Udoskonalone sposoby oczyszczania rekombinowanych wektorów AAV

Info

Publication number
PL3067417T3
PL3067417T3 PL16166278T PL16166278T PL3067417T3 PL 3067417 T3 PL3067417 T3 PL 3067417T3 PL 16166278 T PL16166278 T PL 16166278T PL 16166278 T PL16166278 T PL 16166278T PL 3067417 T3 PL3067417 T3 PL 3067417T3
Authority
PL
Poland
Prior art keywords
purification
improved methods
aav vectors
recombinant aav
recombinant
Prior art date
Application number
PL16166278T
Other languages
English (en)
Inventor
Paulene Mclean Quigley Sheldon
Peter S. Gagnon
Gina Nichols
Barbara A. Thorne
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL3067417T3 publication Critical patent/PL3067417T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02Recovery or purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N2030/022Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027Liquid chromatography

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicinal Preparation (AREA)
PL16166278T 2009-06-16 2010-06-16 Udoskonalone sposoby oczyszczania rekombinowanych wektorów AAV PL3067417T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18760109P 2009-06-16 2009-06-16
EP16166278.8A EP3067417B1 (en) 2009-06-16 2010-06-16 Improved methods for purification of recombinant aav vectors
EP10790155.5A EP2443233B1 (en) 2009-06-16 2010-06-16 Improved methods for purification of recombinant aav vectors
PCT/US2010/038897 WO2010148143A1 (en) 2009-06-16 2010-06-16 Improved methods for purification of recombinant aav vectors

Publications (1)

Publication Number Publication Date
PL3067417T3 true PL3067417T3 (pl) 2019-02-28

Family

ID=43356746

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16166278T PL3067417T3 (pl) 2009-06-16 2010-06-16 Udoskonalone sposoby oczyszczania rekombinowanych wektorów AAV
PL10790155T PL2443233T3 (pl) 2009-06-16 2010-06-16 Udoskonalone sposoby oczyszczania rekombinowanych wektorów AAV

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10790155T PL2443233T3 (pl) 2009-06-16 2010-06-16 Udoskonalone sposoby oczyszczania rekombinowanych wektorów AAV

Country Status (24)

Country Link
US (3) US10017746B2 (pl)
EP (4) EP3067417B1 (pl)
JP (3) JP5956331B2 (pl)
KR (2) KR101812813B1 (pl)
CN (2) CN105861454B (pl)
BR (1) BRPI1015176B1 (pl)
CA (2) CA2764176C (pl)
CY (3) CY1117936T1 (pl)
DK (2) DK3444335T3 (pl)
ES (3) ES2588990T3 (pl)
HK (1) HK1165830A1 (pl)
HR (2) HRP20181743T1 (pl)
HU (3) HUE054940T2 (pl)
IL (3) IL216960A (pl)
LT (2) LT3067417T (pl)
MX (2) MX2011013613A (pl)
PL (2) PL3067417T3 (pl)
PT (3) PT3444335T (pl)
RS (2) RS57784B1 (pl)
RU (1) RU2016119739A (pl)
SG (2) SG176283A1 (pl)
SI (2) SI3444335T1 (pl)
TR (1) TR201815937T4 (pl)
WO (1) WO2010148143A1 (pl)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2018421B1 (en) 2006-04-28 2012-12-19 The Trustees of the University of Pennsylvania Scalable production method for aav
DK3444335T3 (da) * 2009-06-16 2021-07-26 Genzyme Corp Forbedrede fremgangsmåder til oprensning af rekombinante aav-vektorer
WO2011088225A1 (en) 2010-01-15 2011-07-21 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
US8895707B2 (en) 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
WO2012106449A1 (en) 2011-02-02 2012-08-09 Bio-Rad Laboratories, Inc. Apatite surface neutralization with alkali solutions
EP3318571B1 (en) 2011-03-16 2021-02-17 F. Hoffmann-La Roche AG Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
WO2012144446A1 (ja) 2011-04-18 2012-10-26 独立行政法人国立精神・神経医療研究センター 薬剤送達粒子及びその製造方法
DK2744895T3 (en) * 2011-09-08 2016-01-04 Uniqure Ip Bv REMOVAL OF INFECTED VIRA FROM AAV PREPARATIONS
US9815695B2 (en) 2012-05-30 2017-11-14 Bio-Rad Laboratories, Inc. In situ restoration of apatite-based chromatography resins
JP6200949B2 (ja) * 2012-05-31 2017-09-20 エイジェンシー フォー サイエンス,テクノロジー アンド リサーチ 固相ウレイドに対する生物学的標的物の選択的結合
GB2525562B (en) * 2013-02-15 2017-10-11 T Gjerde Douglas Methods for purification of biological cells
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
AU2014232879B2 (en) * 2013-03-15 2020-03-05 The Children's Hospital Of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
EP3741385A1 (en) 2013-04-17 2020-11-25 Genzyme Corporation Compositions for use in a method of treating and preventing macular degeneration
CN105339495A (zh) * 2013-07-11 2016-02-17 宝生物工程株式会社 制备无包膜病毒的方法
JP6719381B2 (ja) 2014-02-06 2020-07-08 ジェンザイム・コーポレーション 黄斑変性を処置し、予防するための組成物および方法
EP3137497B1 (en) 2014-05-02 2021-04-07 Genzyme Corporation Aav vectors for retinal and cns gene therapy
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
US10092857B2 (en) 2014-06-23 2018-10-09 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
US9802822B2 (en) 2014-06-23 2017-10-31 Bio-Rad Laboratories, Inc. Apatite pretreatment
JP6521965B2 (ja) 2014-07-10 2019-05-29 タカラバイオ株式会社 非エンベロープウイルス粒子の製造方法
CN104232687A (zh) * 2014-09-17 2014-12-24 许瑞安 一种重组腺相关病毒rAAV载体的分离纯化方法
JP6401871B2 (ja) 2014-11-05 2018-10-10 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. パーキンソン病の治療のためのaadcポリヌクレオチド
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
EP3218484A4 (en) 2014-11-14 2018-05-30 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
WO2016111343A1 (ja) 2015-01-09 2016-07-14 タカラバイオ株式会社 非エンベロープウイルス粒子の製造方法
IL296391B1 (en) 2015-01-20 2024-02-01 Genzyme Corp Analytical ultracentrifugation for characterization of recombinant viral particles
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3054006A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
CN116019934A (zh) 2015-02-10 2023-04-28 建新公司 病毒颗粒至纹状体和皮质的增强递送
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
CN105907729B (zh) * 2015-05-05 2019-08-16 广东东阳光药业有限公司 一种制备人乳头瘤病毒l1蛋白类病毒样颗粒的方法
US20170067028A1 (en) * 2015-05-15 2017-03-09 Douglas J. Ballon Radiolabeling of adeno associated virus
PT3298134T (pt) 2015-05-16 2023-08-18 Genzyme Corp Edição génica de mutações intrónicas profundas
US9663766B2 (en) 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
EP3992283A1 (en) 2015-12-11 2022-05-04 The Trustees Of The University Of Pennsylvania Scalable purification method for aavrh10
EP4215605A1 (en) 2015-12-11 2023-07-26 The Trustees of The University of Pennsylvania Scalable purification method for aav8
WO2017160360A2 (en) 2015-12-11 2017-09-21 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
US11015173B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV1
EP3390644A1 (en) 2015-12-15 2018-10-24 Genzyme Corporation Adeno-associated viral vectors for treating mucolipidosis type ii
WO2017112948A1 (en) * 2015-12-24 2017-06-29 University Of Florida Research Foundation, Inc. Improved aav production using suspension adapted cells
BR112018069703A2 (pt) 2016-03-28 2019-02-05 Dimension Therapeutics Inc métodos de inativação de adenovírus por calor
ES2896080T3 (es) * 2016-03-31 2022-02-23 Spark Therapeutics Inc Procedimiento en columna totalmente escalable de preparación de VAAr
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
GB201608046D0 (en) 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
WO2017201258A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
EP3458588A4 (en) 2016-05-18 2020-01-15 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
GB201612248D0 (en) 2016-07-14 2016-08-31 Puridify Ltd New process
MX2019001938A (es) 2016-08-15 2019-07-04 Genzyme Corp Metodos para detectar aav.
KR102369014B1 (ko) 2016-08-16 2022-03-02 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
US20190185864A1 (en) 2016-08-23 2019-06-20 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
EP3831281A1 (en) 2016-08-30 2021-06-09 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
EP3526321A4 (en) 2016-10-14 2020-05-13 Ultragenyx Pharmaceutical Inc. USE OF TONIFYING AGENTS TO IMPROVE THE YIELD OF RECOMBINANT ADENO-ASSOCIATED VIRUS
PL3532838T3 (pl) 2016-10-25 2022-10-03 Regeneron Pharmaceuticals, Inc. Metody i systemy analizy danych chromatograficznych
ES2948849T3 (es) * 2016-11-04 2023-09-20 Takeda Pharmaceuticals Co Métodos de purificación de virus adenoasociado
US10626376B2 (en) * 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
US11898170B2 (en) 2017-03-22 2024-02-13 Ultragenyx Pharmaceutical Inc. Cell culture methods involving HDAC inhibitors or rep proteins
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. 筋萎縮性側索硬化症(als)治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
PE20200737A1 (es) * 2017-06-30 2020-07-23 Spark Therapeutics Inc Metodos de purificacion de columna de vector aav
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
AU2018352236A1 (en) 2017-10-16 2020-04-23 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
AU2018395254A1 (en) * 2017-12-29 2020-06-25 Takeda Pharmaceutical Company Limited Adeno-associated virus purification methods
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
EP3755795A4 (en) 2018-02-19 2022-07-20 Homology Medicines, Inc. ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RECOVERING F8 GENE FUNCTION AND METHODS OF USE THEREOF
WO2019212921A1 (en) * 2018-04-29 2019-11-07 Regenxbio Inc. Scalable clarification process for recombinant aav production
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EP3826719A1 (en) * 2018-07-24 2021-06-02 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
JP7070238B2 (ja) * 2018-08-22 2022-05-18 株式会社島津製作所 液体クロマトグラフ分析装置、移動相供給装置、液体クロマトグラフ分析方法および移動相供給方法
CA3112824A1 (en) * 2018-09-21 2020-03-26 Nightstarx Limited Compositions and methods for manufacturing gene therapy vectors
US20210348135A1 (en) 2018-10-12 2021-11-11 Genzyme Corporation Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
CN113302290A (zh) 2018-11-16 2021-08-24 编码治疗公司 治疗威尔逊氏病的组合物和方法
JP2022530126A (ja) 2019-04-23 2022-06-27 アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) 新規アデノ随伴ウイルス(aav)バリアント及び遺伝子治療のためのその使用
US10557149B1 (en) 2019-07-15 2020-02-11 Vigene Biosciences, Inc. Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
US10801042B1 (en) 2019-07-15 2020-10-13 Vigene Biosciences, Inc. Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
US10653731B1 (en) 2019-07-15 2020-05-19 Vigene Biosciences Inc. Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
US20210261625A1 (en) 2020-01-29 2021-08-26 Genzyme Corporation Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
CA3168055A1 (en) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
EP3919613A1 (en) * 2020-06-05 2021-12-08 Bia Separations D.O.O. Enhanced purification of adeno-associated virus to more effectively remove contaminating dna
WO2021255835A1 (ja) * 2020-06-16 2021-12-23 HOYA Technosurgical株式会社 アパタイトカラムを使用したウイルスの精製方法
CN111808828B (zh) * 2020-09-14 2020-11-17 和元生物技术(上海)股份有限公司 腺相关病毒的分离纯化方法
WO2022072657A1 (en) 2020-10-01 2022-04-07 Genzyme Corporation Human pah expression cassette for treatment of pku by liver-directed gene replacement therapy
EP4299751A1 (en) 2021-03-09 2024-01-03 JCR Pharmaceuticals Co., Ltd. Method for producing recombinant aav9 virion
JP2024511409A (ja) 2021-03-22 2024-03-13 ジェンザイム・コーポレーション 空および完全aavキャプシドのサイズ排除クロマトグラフィー解析
WO2023201272A1 (en) 2022-04-12 2023-10-19 Genzyme Corporation Use of irak4 modulators for gene therapy
WO2023201274A1 (en) 2022-04-12 2023-10-19 Genzyme Corporation Use of an irak4 modulator for gene therapy
US20230407255A1 (en) 2022-04-12 2023-12-21 Genzyme Corporation Dendritic cell assay for innate immunogenicity to gene therapy agents
US20230346977A1 (en) 2022-04-13 2023-11-02 Universitat Autònoma De Barcelona Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
US20230398192A1 (en) 2022-05-16 2023-12-14 Genzyme Corporation Methods of treating metachromatic leukodystrophy
WO2023240062A1 (en) 2022-06-07 2023-12-14 Adverum Biotechnologies, Inc. Melanopsin variants for vision restoration

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2625279A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
EP1009808B1 (en) 1997-09-05 2012-12-05 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
EP1841863B1 (en) * 2005-01-14 2010-08-04 Bayer HealthCare LLC Method for purification of factor vii
HUE028605T2 (en) * 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
GB2467320A (en) 2009-01-28 2010-08-04 Surrey Nanosystems Ltd Two methods of forming carbon nano-materials using filtered acetylene gas
DK3444335T3 (da) 2009-06-16 2021-07-26 Genzyme Corp Forbedrede fremgangsmåder til oprensning af rekombinante aav-vektorer

Also Published As

Publication number Publication date
DK3444335T3 (da) 2021-07-26
CN102803478A (zh) 2012-11-28
JP6496684B2 (ja) 2019-04-03
CY1121442T1 (el) 2020-05-29
US11840710B2 (en) 2023-12-12
US10696952B2 (en) 2020-06-30
PL2443233T3 (pl) 2017-08-31
HUE028341T2 (en) 2016-12-28
HRP20181743T1 (hr) 2019-02-22
US10017746B2 (en) 2018-07-10
HUE040636T2 (hu) 2019-03-28
KR20120047213A (ko) 2012-05-11
RS57784B1 (sr) 2018-12-31
PT3444335T (pt) 2021-07-12
US20150024467A1 (en) 2015-01-22
IL253205B (en) 2018-07-31
JP2016195600A (ja) 2016-11-24
CA3077531C (en) 2022-09-20
LT3067417T (lt) 2018-11-12
HK1165830A1 (zh) 2012-10-12
CA2764176A1 (en) 2010-12-23
SI3444335T1 (sl) 2021-08-31
CY1124323T1 (el) 2022-07-22
EP3444335A1 (en) 2019-02-20
US20210139860A1 (en) 2021-05-13
LT3444335T (lt) 2021-07-26
IL216960A0 (en) 2012-02-29
HRP20211120T1 (hr) 2021-10-15
WO2010148143A1 (en) 2010-12-23
EP2443233A4 (en) 2013-05-29
PT2443233T (pt) 2016-08-17
PT3067417T (pt) 2018-11-13
BRPI1015176B1 (pt) 2019-10-29
SG10201403290SA (en) 2014-10-30
IL260215A (en) 2018-07-31
RS62086B1 (sr) 2021-08-31
EP3067417B1 (en) 2018-07-25
JP2019083822A (ja) 2019-06-06
JP6788056B2 (ja) 2020-11-18
IL216960A (en) 2017-07-31
HUE054940T2 (hu) 2021-10-28
ES2588990T3 (es) 2016-11-08
TR201815937T4 (tr) 2018-11-21
JP2012529917A (ja) 2012-11-29
US20190010468A1 (en) 2019-01-10
CA2764176C (en) 2020-06-02
CY1117936T1 (el) 2017-05-17
EP3067417A3 (en) 2016-11-02
ES2693194T3 (es) 2018-12-10
DK3067417T3 (en) 2018-11-19
CN105861454B (zh) 2020-03-03
SI3067417T1 (sl) 2018-11-30
MX352986B (es) 2017-12-15
EP2443233B1 (en) 2016-06-01
JP5956331B2 (ja) 2016-07-27
CN105861454A (zh) 2016-08-17
IL253205A0 (en) 2017-08-31
EP2443233A1 (en) 2012-04-25
EP3067417A2 (en) 2016-09-14
ES2881050T3 (es) 2021-11-26
CA3077531A1 (en) 2010-12-23
KR20180000341A (ko) 2018-01-02
RU2012101475A (ru) 2013-07-27
CN102803478B (zh) 2016-04-27
SG176283A1 (en) 2012-01-30
BRPI1015176A2 (pt) 2017-09-26
EP3444335B1 (en) 2021-04-14
EP3919614A1 (en) 2021-12-08
KR101812813B1 (ko) 2017-12-27
RU2016119739A (ru) 2018-11-05
MX2011013613A (es) 2012-01-19

Similar Documents

Publication Publication Date Title
HRP20181743T1 (hr) Poboljšani postupci za pročišćavanje rekombinantnih aav vektora
IL221158B (en) Methods for vector purification of the aav virus
IL225650A0 (en) Protein purification processes
HK1246330A1 (zh) 蛋白質純化
PL2307551T3 (pl) Oczyszczanie wektorów retrowirusowych
IL228610B (en) Buffer system for protein purification
HUE050305T2 (hu) Eljárások izocianát keverékek tisztítására
IL215562A0 (en) Process for isolating therapeutic peptide
SI2552941T1 (sl) Čiščenje vmesnih spojin kaspofungina
EP2519537A4 (en) CLEANING PROTEINS
EP2478010A4 (en) PART PEPTIDE OF LACRITINE
IL231876A0 (en) A system for the purification of viral vectors
GB2479279B (en) Recombinant antigen for detection of toxocariasis